Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

CERS vs NTRA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CERS
Cerus Corporation

Medical - Devices

HealthcareNASDAQ • US
Market Cap$519M
5Y Perf.-58.4%
NTRA
Natera, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$29.58B
5Y Perf.+390.5%

CERS vs NTRA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CERS logoCERS
NTRA logoNTRA
IndustryMedical - DevicesMedical - Diagnostics & Research
Market Cap$519M$29.58B
Revenue (TTM)$217M$2.12B
Net Income (TTM)$-10M$-309M
Gross Margin53.0%63.7%
Operating Margin-8.2%-16.6%
Total Debt$97M$187M
Cash & Equiv.$20M$946M

CERS vs NTRALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CERS
NTRA
StockMay 20May 26Return
Cerus Corporation (CERS)10041.6-58.4%
Natera, Inc. (NTRA)100490.5+390.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: CERS vs NTRA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CERS leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Natera, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CERS
Cerus Corporation
The Value Play

CERS carries the broadest edge in this set and is the clearest fit for value and quality.

  • Better valuation composite
  • -4.4% margin vs NTRA's -14.6%
  • +107.2% vs NTRA's +38.3%
Best for: value and quality
NTRA
Natera, Inc.
The Income Pick

NTRA is the clearest fit if your priority is income & stability and growth exposure.

  • beta 1.26
  • Rev growth 56.7%, EPS growth 59.5%, 3Y rev CAGR 39.5%
  • 21.5% 10Y total return vs CERS's -53.0%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthNTRA logoNTRA56.7% revenue growth vs CERS's 14.3%
ValueCERS logoCERSBetter valuation composite
Quality / MarginsCERS logoCERS-4.4% margin vs NTRA's -14.6%
Stability / SafetyNTRA logoNTRABeta 1.26 vs CERS's 2.13, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)CERS logoCERS+107.2% vs NTRA's +38.3%
Efficiency (ROA)CERS logoCERS-4.4% ROA vs NTRA's -17.0%, ROIC -19.7% vs -33.3%

CERS vs NTRA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CERSCerus Corporation
FY 2025
Product
88.2%$206M
Government Contract
11.8%$28M
NTRANatera, Inc.
FY 2025
Product
99.6%$2.3B
Licensing and other
0.4%$10M

CERS vs NTRA — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCERSLAGGINGNTRA

Income & Cash Flow (Last 12 Months)

Evenly matched — CERS and NTRA each lead in 3 of 6 comparable metrics.

NTRA is the larger business by revenue, generating $2.1B annually — 9.8x CERS's $217M. CERS is the more profitable business, keeping -4.4% of every revenue dollar as net income compared to NTRA's -14.6%. On growth, NTRA holds the edge at +34.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCERS logoCERSCerus CorporationNTRA logoNTRANatera, Inc.
RevenueTrailing 12 months$217M$2.1B
EBITDAEarnings before interest/tax-$16M-$315M
Net IncomeAfter-tax profit-$10M-$309M
Free Cash FlowCash after capex-$1M$94M
Gross MarginGross profit ÷ Revenue+53.0%+63.7%
Operating MarginEBIT ÷ Revenue-8.2%-16.6%
Net MarginNet income ÷ Revenue-4.4%-14.6%
FCF MarginFCF ÷ Revenue-0.6%+4.4%
Rev. Growth (YoY)Latest quarter vs prior year+24.1%+34.7%
EPS Growth (YoY)Latest quarter vs prior year+75.7%-146.2%
Evenly matched — CERS and NTRA each lead in 3 of 6 comparable metrics.

Valuation Metrics

CERS leads this category, winning 3 of 4 comparable metrics.
MetricCERS logoCERSCerus CorporationNTRA logoNTRANatera, Inc.
Market CapShares × price$519M$29.6B
Enterprise ValueMkt cap + debt − cash$596M$28.8B
Trailing P/EPrice ÷ TTM EPS-31.59x-140.58x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue2.52x17.43x
Price / BookPrice ÷ Book value/share7.60x22.44x
Price / FCFMarket cap ÷ FCF60.90x427.23x
CERS leads this category, winning 3 of 4 comparable metrics.

Profitability & Efficiency

CERS leads this category, winning 5 of 9 comparable metrics.

CERS delivers a -15.2% return on equity — every $100 of shareholder capital generates $-15 in annual profit, vs $-25 for NTRA. NTRA carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to CERS's 1.49x. On the Piotroski fundamental quality scale (0–9), NTRA scores 6/9 vs CERS's 5/9, reflecting solid financial health.

MetricCERS logoCERSCerus CorporationNTRA logoNTRANatera, Inc.
ROE (TTM)Return on equity-15.2%-24.7%
ROA (TTM)Return on assets-4.4%-17.0%
ROICReturn on invested capital-19.7%-33.3%
ROCEReturn on capital employed-28.1%-18.1%
Piotroski ScoreFundamental quality 0–956
Debt / EquityFinancial leverage1.49x0.16x
Net DebtTotal debt minus cash$77M-$758M
Cash & Equiv.Liquid assets$20M$946M
Total DebtShort + long-term debt$97M$187M
Interest CoverageEBIT ÷ Interest expense-2.63x-69.90x
CERS leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

NTRA leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in NTRA five years ago would be worth $22,333 today (with dividends reinvested), compared to $4,346 for CERS. Over the past 12 months, CERS leads with a +107.2% total return vs NTRA's +38.3%. The 3-year compound annual growth rate (CAGR) favors NTRA at 59.4% vs CERS's 5.4% — a key indicator of consistent wealth creation.

MetricCERS logoCERSCerus CorporationNTRA logoNTRANatera, Inc.
YTD ReturnYear-to-date+31.5%-6.0%
1-Year ReturnPast 12 months+107.2%+38.3%
3-Year ReturnCumulative with dividends+17.2%+305.1%
5-Year ReturnCumulative with dividends-56.5%+123.3%
10-Year ReturnCumulative with dividends-53.0%+2147.5%
CAGR (3Y)Annualised 3-year return+5.4%+59.4%
NTRA leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

NTRA leads this category, winning 2 of 2 comparable metrics.

NTRA is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than CERS's 2.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.

MetricCERS logoCERSCerus CorporationNTRA logoNTRANatera, Inc.
Beta (5Y)Sensitivity to S&P 5002.13x1.26x
52-Week HighHighest price in past year$3.15$256.36
52-Week LowLowest price in past year$1.15$131.81
% of 52W HighCurrent price vs 52-week peak+82.2%+83.9%
RSI (14)Momentum oscillator 0–10070.651.9
Avg Volume (50D)Average daily shares traded2.1M1.3M
NTRA leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates CERS as "Buy" and NTRA as "Buy". Consensus price targets imply 54.4% upside for CERS (target: $4) vs 22.0% for NTRA (target: $263).

MetricCERS logoCERSCerus CorporationNTRA logoNTRANatera, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$4.00$262.50
# AnalystsCovering analysts1027
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

CERS leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). NTRA leads in 2 (Total Returns, Risk & Volatility). 1 tied.

Best OverallCerus Corporation (CERS)Leads 2 of 6 categories
Loading custom metrics...

CERS vs NTRA: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is CERS or NTRA a better buy right now?

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 56. 7% revenue growth year-over-year, versus 14. 3% for Cerus Corporation (CERS). Analysts rate Cerus Corporation (CERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — CERS or NTRA?

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +123. 3%, compared to -56. 5% for Cerus Corporation (CERS). Over 10 years, the gap is even starker: NTRA returned +21. 5% versus CERS's -53. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — CERS or NTRA?

By beta (market sensitivity over 5 years), Natera, Inc.

(NTRA) is the lower-risk stock at 1. 26β versus Cerus Corporation's 2. 13β — meaning CERS is approximately 70% more volatile than NTRA relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 16% versus 149% for Cerus Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — CERS or NTRA?

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 56. 7% versus 14. 3% for Cerus Corporation (CERS). On earnings-per-share growth, the picture is similar: Natera, Inc. grew EPS 59. 5% year-over-year, compared to 25. 5% for Cerus Corporation. Over a 3-year CAGR, NTRA leads at 39. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — CERS or NTRA?

Cerus Corporation (CERS) is the more profitable company, earning -7.

6% net margin versus -11. 2% for Natera, Inc. — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NTRA leads at -13. 1% versus -17. 6% for CERS. At the gross margin level — before operating expenses — NTRA leads at 60. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — CERS or NTRA?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is CERS or NTRA better for a retirement portfolio?

For long-horizon retirement investors, Natera, Inc.

(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Cerus Corporation (CERS) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRA: +21. 5%, CERS: -53. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between CERS and NTRA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CERS is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

CERS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 12%
  • Gross Margin > 31%
Run This Screen
Stocks Like

NTRA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 17%
  • Gross Margin > 38%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CERS and NTRA on the metrics below

Revenue Growth>
%
(CERS: 24.1% · NTRA: 34.7%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.